Scholars Central

Conference abstractPublished 2021

Systemic Cell Therapy using human mononuclear cord blood cells (hUCBCs) in patients with Acute Severe Contusion Spinal Cord Injury (ASIA A, B): Phases I/IIa of randomized open-label safety and primary efficiency clinical study

Authors: Vladimir A Smirnov, Andrew A Grin, Sergey I Ryabov, Marina A Zvyagintseva, Mikhail Yadgarov, Sergey Bazanovich, Vladimir N Smirnov

Sklifosovsky Emergency Care Research Institute, Russia National Medical Institute of Cardiology, Russia

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Introduction: Spinal Cord Injury (SCI) is a severe injury of CNS resulting in disability and a significant decrease in quality of life. The uncomplicated injury of the spine is easily and effectively treated in almost all cases using current surgical techniques, but no effective treatment of SCI is currently available. We published earlier the results of a preclinical study series using human mononuclear UCBCs in animal models of SCI. These studies demonstrated the high efficiency of systemic cell therapy resulted in regression of motor deficit up to 53% compared to placebo and decrease in myelopathy area volume according to 7,0 Tl MRI examination. Materials and Methods: Phases I/IIa randomized open-label clinical study of cell therapy safety and primary efficiency in patients with acute contusion SCI and ASIA A/B neurological deficit was carried out. 20 patients were included in the study divided into 2 groups. Treated patients obtained 4 IV infusions of 300 x 106 mononuclear hUCBCs weekly. The follow-up period reached 1 year. Results: The performed study was approved by Institutional Review Board and registered in the ClinicalTrials.gov portal. Safety evaluation was carried out using CTCAE v5.0 classification. The overall amount of 392 adverse events was registered in 20 patients. Only 2 of them were likely to be related to cell therapy, both were moderate. No other side effects or complications related to cell therapy were detected in all patients. No signs of immunization were observed. The conducted efficiency analysis demonstrated restoration of spinal cord functions and improvement of outcomes compared to routine therapy. The mean increase of the ASIA scale in the experimental group reached 2.2 while in the control group it was 0.9. The total index of motor scale in upper extremities (UEMS) and lower extremities (LEMS) in the treated group reached 77 ± 19 points while in the control group it was 33 ± 21.6. 78% of treated patients were able to stand and walk autonomously while in the control group only 30% were able to perform that. Cell therapy also decreased the spasticity level in lower extremities assessed by the modified Ashworth scale and promoted the improvement in self-urination ability in patients with neurological urinary retention. Quality of life was also significantly higher in the cell therapy group according to the FIM scale. Conclusion: Thus systemic cell therapy utilizing mononuclear human UCBCs is a safe and effective method of regenerative therapy on acute contusion SCI.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Spine & Neurosurgery
  • SubjectNeuroscience & Neurology
  • SubjectOrthopaedics
  • BylineArticles whose byline prints “Vladimir A Smirnov”
  • BylineArticles whose byline prints “Andrew A Grin”
  • BylineArticles whose byline prints “Sergey I Ryabov”
  • BylineArticles whose byline prints “Marina A Zvyagintseva”
  • BylineArticles whose byline prints “Mikhail Yadgarov”
  • BylineArticles whose byline prints “Sergey Bazanovich”
  • BylineArticles whose byline prints “Vladimir N Smirnov”